The pharma company said it has signed share transfer agreements with all individual shareholders of Gennova to acquire 663,865 equity shares, representing 12.05% of the company’s paid-up equity capital.
The pharma company said it has signed share transfer agreements with all individual shareholders of Gennova to acquire 663,865 equity shares, representing 12.05% of the company’s paid-up equity capital.